Pulmonx Corporation (LUNG) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.95
↓-72% vs avg
5yr avg: 3.38
30Y Low1.7·High10.9
ROE
↓
-77.2%
↑-65% vs avg
5yr avg: -46.9%
30Y Low-166%·High-23%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
LUNG Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Pulmonx Corporation currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $54M | $90M | $266M | $484M | $313M | $1.2B | $2.5B | — | — |
| Enterprise Value | $40M | $76M | $251M | $442M | $235M | $1.0B | $2.3B | — | — |
| P/E Ratio → | -0.95 | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.59 | 0.99 | 3.17 | 7.05 | 5.83 | 23.93 | 75.26 | — | — |
| P/B Ratio | 0.95 | 1.66 | 3.09 | 4.09 | 2.03 | 6.00 | 10.89 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
LUNG EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.84 | 3.00 | 6.44 | 4.39 | 21.41 | 69.01 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
LUNG Profitability
Margins and return-on-capital ratios measuring operating efficiency
Pulmonx Corporation earns an operating margin of -59.3%. Operating margins have expanded from -90.2% to -59.3% over the past 3 years, signaling improving operational efficiency. A negative ROE of -77.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 74.2% | 74.2% | 74.0% | 73.9% | 74.3% | 73.6% | 64.8% | 68.8% | 61.4% |
| Operating Margin | -59.3% | -59.3% | -68.9% | -90.2% | -109.3% | -97.7% | -98.8% | -54.7% | -75.2% |
| Net Profit Margin | -59.7% | -59.7% | -67.3% | -88.6% | -109.8% | -100.5% | -98.5% | -63.5% | -92.4% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -77.2% | -77.2% | -55.3% | -44.7% | -33.9% | -23.2% | -166.3% | — | — |
| ROA | -37.0% | -37.0% | -33.1% | -32.8% | -27.5% | -19.5% | -20.3% | -60.4% | -123.1% |
| ROIC | -72.0% | -72.0% | -58.7% | -60.8% | -59.5% | -76.5% | -104.1% | -53.5% | — |
| ROCE | -43.3% | -43.3% | -39.4% | -37.6% | -29.9% | -20.2% | -22.3% | -77.0% | -216.9% |
LUNG Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $70M exceeds total debt of $56M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.04 | 1.04 | 0.66 | 0.35 | 0.16 | 0.14 | 0.12 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.25 | -0.17 | -0.36 | -0.50 | -0.63 | -0.90 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -17.01 | -17.01 | -14.94 | -17.65 | -53.94 | -57.28 | -9.07 | -7.78 | -6.33 |
Net cash position: cash ($70M) exceeds total debt ($56M)
LUNG Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Pulmonx Corporation's current ratio of 5.07x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 4.28x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 6.50x to 5.07x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.07 | 5.07 | 5.58 | 6.50 | 9.14 | 11.85 | 19.96 | 2.90 | 1.40 |
| Quick Ratio | 4.28 | 4.28 | 4.88 | 5.77 | 8.35 | 10.92 | 19.10 | 2.50 | 0.99 |
| Cash Ratio | 3.49 | 3.49 | 4.15 | 5.06 | 7.63 | 10.26 | 18.50 | 2.00 | 0.51 |
| Asset Turnover | — | 0.70 | 0.51 | 0.39 | 0.28 | 0.21 | 0.12 | 0.61 | 1.33 |
| Inventory Turnover | 1.47 | 1.47 | 1.29 | 1.07 | 0.95 | 0.79 | 1.07 | 1.81 | 2.32 |
| Days Sales Outstanding | — | 48.69 | 60.08 | 69.20 | 63.11 | 52.20 | 50.93 | 67.17 | 62.42 |
LUNG Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Pulmonx Corporation does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $41M | $39M | $38M | $37M | $36M | $36M | $35M | $21M |
Peer Comparison
Compare LUNG with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 LUNGYou | $54M | -1.0 | — | — | 74.2% | -59.3% | -77.2% | -72.0% | — |
 INSP | $1B | 9.3 | 19.1 | 16.7 | 85.4% | 5.6% | 19.8% | 6.0% | 0.5 |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 ATRC | $1B | -115.8 | 77.7 | 29.2 | 74.4% | -0.6% | -2.4% | -0.6% | 5.2 |
 PRCT | $1B | -14.8 | — | — | 63.7% | -33.7% | -24.9% | -55.7% | — |
 MMSI | $4B | 29.3 | 13.1 | 17.2 | 48.7% | 12.2% | 8.7% | 7.2% | 2.8 |
 ANGO | $469M | -13.6 | — | — | 53.9% | -13.7% | -17.5% | -22.9% | — |
 TMDX | $3B | 15.0 | 18.4 | 18.9 | 59.9% | 17.9% | 54.2% | 18.8% | 3.5 |
 MDT | $100B | 21.6 | 14.3 | 19.3 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 BSX | $84B | 29.2 | 25.3 | 23.0 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
 SYK | $113B | 35.0 | 20.3 | 26.3 | 64.0% | 19.5% | 15.1% | 11.4% | 2.4 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See LUNG's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LUNG Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LUNG vs INSP
Side-by-side business, growth, and profitability comparison vs Inspire Medical Systems, Inc..
Start ComparisonLUNG — Frequently Asked Questions
Quick answers to the most common questions about buying LUNG stock.
What is Pulmonx Corporation's P/E ratio?
Pulmonx Corporation's current P/E ratio is -1.0x. This places it at the 50th percentile of its historical range.
What is Pulmonx Corporation's ROE?
Pulmonx Corporation's return on equity (ROE) is -77.2%. The historical average is -66.8%.
Is LUNG stock overvalued?
Based on historical data, Pulmonx Corporation is trading at a P/E of -1.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Pulmonx Corporation's profit margins?
Pulmonx Corporation has 74.2% gross margin and -59.3% operating margin.